Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 608-613

  Navo, Marisa ^a   Kunthur, Anuradha ^b   Badell, Martina L ^c   Coffer II, Larry W ^b   Markman, Maurie ^b   Brown, Jubilee ^b   Smith, Judith A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UTMDACC   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Allergy; Cancer; Carboplatin; Hypersensitivity; Oncology

Indexed keywords

CARBOPLATIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ANAMNESIS; ARTICLE; CANCER CENTER; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DATA COLLECTION METHOD; DEMOGRAPHY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INFORMATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL RECORD; OVARY CANCER; PATIENT IDENTIFICATION; PHARMACY; PREMEDICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 33750181639     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.04.002     Document Type: Article

References (24)

1. Polyzos A., Tsavaris N., Kosmas C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61 (2001) 129-133
2. Sliesoraitis S., and Chikhale P.J. Carboplatin hypersensitivity. Int. J. Gynecol. Cancer 15 (2005) 13-18
3. Sood A.K., Gelder M.S., Huang S.W., et al. Anaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol. Oncol. 57 (1995) 131-132
4. Riedl M.A., and Casillas Q.M. Adverse drug reactions: types and treatment options. Am. Fam. Phys. 68 (2003) 1781-1790
5. Pichler W.J. Immune mechanism of drug hypersensitivity. Immunol. Allergy Clin. North Am. 24 (2004) 373-397
6. Shepherd G.M. Hypersensitivity reactions to drugs: evaluation and management. Mt. Sinai J. Med. 70 (2003) 113-125
7. Markman M., Kennedy A., Webster K., et al. Clinical features of hypersensitivity reactions to carboplatin. J. Clin. Oncol. 17 (1999) 1141-1145
8. Vandebriel R.J. Gene polymorphisms within the immune system that may underlie drug allergy. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 125-132
9. Tonkin K.S., Rubin P., and Levin L. Carboplatin hypersensitivity: case reports and review of the literature. Eur. J. Cancer 29A (1993) 1356-1357
10. Weidmann B., Mulleneisen N., Bojko P., et al. Hypersensitivity reactions to carboplatin. Cancer 73 (1994) 2218-2222
11. Kawano S., Kohmura H., Ohta S., et al. Antigenicity study of carboplatin in guinea pigs and mice. J. Toxicol. Sci. 13 Suppl. 2 (1988) 1-21
12. Zanotti K.M., Rybicki L.A., Kennedy A.W., et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J. Clin. Oncol. 19 (2001) 3126-3129
13. Cleare M.J., Highes E.G., Jacoby B., et al. Immediate (Type I) allergic responses to platinum compounds. Clin. Allergy 6 (1976) 183-195
14. Raulf-Heimsoth M., Merget R., Rihs H.P., et al. T-cell receptor repertoire expression in workers with occupational asthma due to platinum salt. Eur. Respir. J. 16 (2000) 871-878
15. Descotes J., and Choquet-Kastylevsky. Gell and coombs's classification: is it still valid?. Toxicology 158 (2001) 42-49
16. Pichler W.J. Delayed drug hypersensitivity reactions. Ann. Intern Med. 139 (2003) 683-693
17. Saunders M.P., Denton C.P., O'Brien M.E.R., et al. Hypersensitivity reactions to cisplatin and carboplatin: a report on six cases. Ann. Oncol. 3 (1992) 574-576
18. Hendrick A.M., Simmons D., and Cantwell B.M.J. Allergic reactions to carboplatin. Ann. Oncol. 3 (1992) 239-240
19. Planner R.S., Weerasiri T., Timmins D., et al. Hypersensitivity reactions to carboplatin. J. Natl. Cancer Inst. 83 (1991) 1763-1764
20. Kandel M.J., Loehr A., Harter P., Traut A., Gnauert K., and Du Bois A. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int. J. Gynecol. Cancer 15 (2005) 780-784
21. Zorzou M.P., Efstathious E., Galani E., et al. Carboplatin hypersensitivity reactions: a single institution experience. Chemotheraphy 17 (2005) 104-110
22. Lee C.W., Matulonis U.A., and Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol. Oncol. 95 (2004) 370-376
23. Robinson J.B., Singh D., Bodurka-Bevers D.C., et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol. Oncol. 82 (2001) 550-558
24. Broome C.B., Schiff R.I., and Friedman H.S. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med. Pediatr. Oncol. 26 (1996) 105-110